Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo

Carcinogenesis

Volumn 25, Issue 7, 2004, Pages 1129-1136

  Pennati, Marzia ^a   Binda, Mara ^a   De Cesare, Michelandrea ^a   Pratesi, Graziella ^a   Folini, Marco ^a   Citti, Lorenzo ^b   Daidone, Maria Grazia ^a   Zunino, Franco ^a   Zaffaroni, Nadia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; CYTOSINE; DNA TOPOISOMERASE INHIBITOR; GUANINE; MESSENGER RNA; RIBOZYME; SURVIVIN; TEMOZOLOMIDE; TOPOTECAN; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CELL NUCLEUS; CELL POPULATION; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME MECHANISM; EXON; FEMALE; GENE MUTATION; GENE TARGETING; GENETIC STABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 9; CASPASES; DNA TOPOISOMERASES, TYPE I; DOWN-REGULATION; HUMANS; MELANOMA; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RNA, CATALYTIC; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS;

EID: 3042552397     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh107     Document Type: Article

References (37)

1. Grossman,D. and Altieri,D.C. (2001) Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev., 20, 3-11.
2. Becker,J.C., Kampgen,E. and Brocker,E. (2000) Classical chemotherapy for metastatic melanoma. Clin. Exp. Dermatol., 25, 503-508.
3. Satyamoorthy,K., Bogenrieder,T. and Herlyn,M. (2001) No longer a molecular black box - new clues to apoptosis and drug resistance in melanoma. Trends Mol. Med., 7, 191-194.
4. Soengas,M.S. and Lowe,S.W. (2003) Apoptosis and melanoma chemoresistance. Oncogene, 22, 3138-3151.
5. Mooney,E.E., Ruis Peris, J.M., O'Neill,A. and Sweeney,E.C. (1995) Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J. Clin. Pathol., 48, 242-244.
6. Thomas,W.D. and Hersey,P. (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediated CD4 T cell killing of target cells. J. Immunol., 161, 2195-2200.
7. Tang,L., Tron,V.A., Reed,J.C., Mah,K.J., Krajewska,M., Li,G., Zhou,X., Ho,V.C. and Trotter,M.J. (1998) Expression of apoptosis regulators in cutaneous malignant melanoma. Clin. Cancer Res., 4, 1865-1871.
8. Soengas,M.S., Capodieci,P., Polsky,D. et al. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 409, 207-211.
9. Vucic,D., Stennicke,H.R., Pisabarro,M.T., Salvesen,G.S. and Dixit,V.M. (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol., 10, 1359-1366.
10. Grossman,D., McNiff,J.M., Li,F. and Altieri,D.C. (1999) Expression and targeting of the apoptosis inhibitor, survivin in human melanoma. J. Invest. Dermatol., 113, 1076-1081.
11. Jansen,B., Schlagbauer-Wadl,H., Brown,B.D., Bryan,R.N., van Elsas,A., Muller,M., Wolff,K., Eichler,H.G. and Pehamberger,H. (1998) bcl-1 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med., 4, 232-234.
12. Thallinger,C., Wolschek,M.F., Wacheck,V. et al. (2003) Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J. Invest. Dermatol., 120, 1081-1086.
13. Jansen,B., Wacheck,V., Heere-Ress,E., Schlagbauer-Wadl,H., Hoeller,C., Lucas,T., Hoermann,M., Hollenstein,U., Wolff,K. and Pehamberger,H. (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet, 356, 1728-1733.
14. Heere-Ress,E., Thallinger,C., Lucas,T., Sachlaugbauer-Wadl,H., Wacheck,V., Monia,B.P., Wolff,K., Pehamberger,H. and Jansen,B. (2002) Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int. J. Cancer, 99, 29-34.
15. Altieri,D.C., Marchisio,P.C. and Marchisio,C. (1999) Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab. Invest., 79, 1327-1333.
16. Altieri,D.C. (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med., 7, 542-547.
17. Grossman,D., Kim,P.J., Schechner,J.S. and Altieri,D.C. (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl Acad. Sci. USA, 98, 635-640.
18. Pennati,M., Colella,G., Folini,M., Citti,L., Daidone,M.G. and Zaffaroni,N. (2002) Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest., 109, 285-286.
19. Mesri,M., Wall,N.R., Li,J., Kim,R.W. and Altieri,D.C. (2001) Cancer gene therapy using a surviving mutant adenovirus. J. Clin. Invest., 108, 981-990.
20. O'Connor,D.S., Wall,N.R., Porter,A.C. and Altieri,D.C. (2002) A p34(cdc2) survival checkpoint in cancer. Cancer Cell, 2, 43-54.
21. Olie,R.A., Simoes-Wust,A.P., Baumann,B., Leech,S.H., Fabbro,D., Stahel,R.A. and Zangemeister-Wittke,U. (2000) A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res., 60, 2805-2809.
22. Wall,N.R., O'Connor,D.S., Plescia,J., Pommier,Y. and Altieri,D.C. (2003) Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res., 63, 230-235.
23. Yamamoto,T., Manome,Y., Nakamura,M. and Tanigawa,N. (2002) Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur. J. Cancer, 38, 2316-2324.
24. Pennati,M., Binda,M., Colella,G., Folini,M., Citti,L., Villa,R., Daidone,M.G. and Zaffaroni,N. (2003) Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J. Invest. Dermatol., 120, 648-654.
25. Workman,P., Twentyman,P., Balkwill,F. et al. (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (ed.2). Br. J. Cancer, 77, 1-10.
26. Sun,L.Q., Cairns,M.J., Saravolac,E.G., Baker,A. and Gerlach,W.L. (2000) Catalytic nucleic acids: from lab to applications. Pharmacol. Rev., 52, 325-347.
27. Lewin,A.S. and Hauswirth,W.W. (2001) Ribozyme gene therapy: applications for molecular medicine. Trends Mol. Med., 7, 221-228.
28. Altieri,D.C. (2003) Blocking survivin to kill cancer cells. Methods Mol. Biol., 223, 533-542.
29. Reed,J.C. (2001) The Survivin saga goes in vivo. J. Clin. Invest., 108, 965-969.
30. O'Connor,D.S., Grossman,D., Plescia,J., Li,F., Zhang,H., Villa,A., Tognin,S., Marchisio,P.C. and Altieri,D.C. (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl Acad. Sci. USA, 97, 13103-13107.
31. Song,Z., Yao,X. and Wu,M. (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during tax induced apoptosis. J. Biol. Chem., 278, 23130-23140.
32. Du,C., Fang,M., Li,Y., Li,L. and Wang,X. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 102, 33-42.
33. Vucic,D., Deshayes,K., Ackerly,H., Pisabarro,M.T., Kadkhodayan,S., Fairbrother,W.J. and Dixit,V.M. (2002) SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J. Biol. Chem., 277, 12275-12279.
34. Altieri,D.C. (1995) Xa receptor EPR-1. FASEB, 9, 860-865.
35. Altieri,D.C. (2003) Survivin and apoptosis control. Adv. Cancer Res., 88, 31-52.
36. Pennati,M., Binda,M., Colella,G. et al. (2004) Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene, 23, 386-394.
37. Pratesi,G., De Cesare,M., Carenini,N. et al. (2002) Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin. Cancer Res., 8, 3904-3909.